Диссертация (Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения), страница 36
Описание файла
Файл "Диссертация" внутри архива находится в папке "Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения". PDF-файл из архива "Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой докторскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени доктора медицинских наук.
Просмотр PDF-файла онлайн
Текст 36 страницы из PDF
Lenaerts I. Ultrastructural and functional remodeling of the couplingbetween Ca2+ influx and sarcoplasmic reticulum Ca2+ release in right atrialmyocytes from experimental persistent atrial fibrillation. / Lenaerts I. [et al.]//Circ Res. - 2009- Vol 105(9)- P.876–885.212. Li Q. Gain-of-function mutation of Nav1.5 in atrial fibrillationenhances cellular excitability and lowers the threshold for action potential firing./Li Q [et al.] // Biochem Biophys Res Commun. – 2009- Vol 380(1)- P.132–137.213. Li X.
Endothelin-1-induced arrhythmogenic Ca2+ signalin isabolished in atrial myocytes of inositol-1,4,5 trisphosphate(IP3)-receptor type 2deficient mice. / Li X [et al.] //Circ Res. – 2005- Vol 96(12)- P.1274–1281.214. Liakopoulos O.J. Statins for prevention of atrial fibrillation aftercardiac surgery: a systematic literature review. / Liakopoulos O.J. [et al.]// JThorac Cardiovasc Surg -2009-Vol 138-P.
678–686.215. Lind, L. Discovery of new biomarkers for atrial fibrillation using acustom-made proteomics chip. / Lind L. [et al.] //Heart. – 2017-Vol 103-P.377–382.216. Lip G.Y. Identifying patients at high risk for stroke despiteanticoagulation: a comparison of contemporary stroke risk stratification schemesin an anticoagulated atrial fibrillation cohort. / Lip G.Y. [et al.] //Stroke. – 2010Vol 41(12)-P.2731-8217.
Lip GY. ABC of atrial fibrillation. History, epidemiology, andimportance of atrial fibrillation./Lip G.Y. [et al.] //BMJ 1995-Vol 311-P.1361–3.246218. Lip GY. Refining clinical risk stratification for predicting stroke andthromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation. / Lip G.Y. [et al.] //Chest 2010-Vol137- P.263–72.219.
Lip GY. Atrial fibrillation./ Lip G.Y. [et al.]// Lancet -2012-vol379-P.648-661220. Liu T. Mineralocorticoid receptor antagonists and atrial fibrillation: ameta-analysis./ Liu T [et al.] // Europace. – 2016- Vol 18(5)- P.672-8.221. Liu T. Uric acid levels and atrial fibrillation in hypertensive patients./Liu T [et al.] //Intern Med -2011-Vol 50-P. 799–803.222.
Liu T. Statin use and development of atrial fibrillation: a systematicreview and meta-analysis of randomized clinical trials and observational studies. /Liu T [et al.] //Int J Cardiol- 2008-Vol 126-P. 160–170.223. Lloyd-Jones D.M. Lifetime risk for development of atrial fibrillation:the Framingham Heart Study. / Lloyd-Jones D.M.
[et al.] //Circulation – 2004Vol 110- P. 1042–1046.224. Lord J. Economic modelling of diagnostic and treatment pathways inNational Institute for Health and Care Excellence clinical guidelines: theModelling Algorithm Pathways in Guidelines (MAPGuide) project. / Lord J. [etal.] //Health Technology Assessment.- 2013-Vol 17(58)- P.435-65225. Lu Y. MicroRNA-328 contributes to adverse electrical remodeling inatrial fibrillation./ Lu Y. [et al.]//Circulation. – 2010- Vol 122(23)- P.2378–2387.226. Lu Z. Atrial fibrillation begets atrial fibrillation: autonomicmechanism for atrial electrical remodeling induced by short-term rapid atrialpacing.
/ Lu Z. [et al.] //Circ Arrhythm Electrophysiol – 2008-Vol 1- P. 184-192.227. Ma X.X. Clinical relevance of left atrial strain to predict recurrenceof atrial fibrillation after catheter ablation: a meta-analysis. / Ma X.X. [et al.]//Echocardiography. – 2016- Vol 33- P.724–733.247228. MacLennan DH. Store overload-induced Ca2+ release as a triggeringmechanism for CPVT and MH episodes caused by mutations in RYR and CASQgenes. / MacLennan DH. [et al.] //J Physiol. -2009- Vol 587-P.3113–3115.229. Madrid AH. Use of irbesartan to maintain sinus rhythm in patientswith long-lasting persistent atrial fibrillation: a prospective and randomized study./ Madrid AH.
[et al.] //Circulation -2002-Vol 106- P. 331–6.230. Madrid AH. Prevention of recurrences in patients with lone atrialfibrillation. The dose-dependent effect of angiotensin II receptor blockers./Madrid AH. [et al.] //J Renin Angiotensin Aldosterone Syst- 2004-Vol 5-P.114 –20.231. Maggioni AP. Valsartan reduces the incidence of atrial fibrillation inpatients with heart failure: results from the Valsartan Heart Failure Trial (ValHeFT). / Maggioni AP.
[et al.] //Am Heart J – 2005 –Vol 145 –P.548–57.232. Magnani JW. Atrial fibrillation: current knowledge and futuredirections in epidemiology and genomics. / Magnani JW [et al.] //Circulation.2011 – Vol 124(18)- P.1982-93.233. Mahida S. Monogenic atrial fibrillation as pathophysiologicalparadigms./ Mahida S. [et al.] // Cardiovasc Res. 2011-Vol 89(4)-P.692–700.234. Makiyama T. A novel SCN5A gain-of-function mutation M1875Tassociated with familial atrial fibrillation./ Makiyama T.
[et al.] // J Am CollCardiol. – 2008-Vol 52(16)- P.1326–1334.235. Manolis AJ. Hypertension and atrial fibrillation: diagnosticapproach, prevention and treatment. Position paper of the Working Group‘Hypertension Arrhythmias and Thrombosis’ of the European Society ofHypertension./ Manolis AJ [et al.] // J Hypertens.- 2012 – Vol 30(2)- P.239-52.236. Marrouche NF.
Association of atrial tissue fibrosis identified bydelayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAFstudy. / Marrouche NF. [et al.] //JAMA- 2014- Vol 311-P.498–506.248237. Matsushita K. Chronic Kidney Disease Prognosis Consortium.Association of estimated glomerular filtration rate and albuminuria with all-causeand cardiovascular mortality in general population cohorts: a collaborative metaanalysis. / Matsushita K. [et al.] //Lancet – 2010- Vol 375-P. 2073-81.238.
Mavrakis H.E. Acute electrophysiological effects of omega-3 fattyacids in human atrial myocardium./ Mavrakis H.E. [et al.] // Eur Heart J – 2006Vol 27- P. 663-670.239. McDowell K. Mechanistic Inquiry into the Role of TissueRemodeling in Fibrotic Lesions in Human Atrial Fibrillation. / McDowell K. [etal.] // Biophysical Journal.- 2013 -Vol 104(12)- P.2764–2773.240. McManus DD. Relation of kidney function and albuminuria withatrial fibrillation (from the Heart and Soul Study)./ McManus DD. [et al.] //Am JCardiol.
– 2009- Vol 104(11)- P.1551-5.241. Milliez P. Evidence for an increased rate of cardiovascular events inpatients with primary aldosteronism./ Milliez P. [et al.]//J Am Coll Cardiol. -2005- Vol 45(8)- P. 1243-8.242. Mitchell GF. Pulse pressure and risk of new-onset atrial fibrillation/Mitchell GF [et al.] // JAMA.
-2007 –Vol 297(7)- P.709-15.243. Miyasaka Y. Coronary ischemic events after first atrial fibrillation:Risk and survival. / Miyasaka Y. [et al.]//Am J Med – 2007- Vol 120- P. 357–363.244. Miyasaka Y. Secular trends in incidence of atrial fibrillation inOlmsted County, Minnesota, 1980 to 2000, and implications on the projectionsfor future prevalence./ Miyasaka Y. [et al.]// Circulation – 2006- Vol 114-P.119-25245. Molin F. N-3 polyunsaturated fatty acids treatment reducevulnerability to inducible atrial fibrillation and lower expression levels ofconnexins in dogs./ Molin F.
[et al.] // Eur Heart J – 2006- Vol 27-P. 892-99.249246. Mont L. Atrial fibrillation progression: How sick is the atrium? /Mont L, Guasch E. // Heart Rhythm. – 2017-Vol 17- P. 1547-1571.247. Mukamal KJ. Alcohol consumption and risk of atrial fibrillation inmen and women: the Copenhagen City Heart Study./ Mukamal KJ. [et al.]//Circulation. – 2005- Vol 112- P.1736–1742.248.
Murakami N. Distinct risk factors of atrial fibrillation in patientswith and without coronary artery disease: a cross-sectional analysis of theBOREAS-CAG Registry data. / Murakami N. [et al.] // Open Heart – 2017- Jan4(1)- P.573.249. Nabauer M. The Registry of the German Competence NETwork onAtrial Fibrillation: patient characteristics and initial management./ Nabauer M. [etal.] //Europace – 2009- Vol 11-P.
423–434.250. Naccarelli G.V. Increasing prevalence of atrial fibril-lation andflutter in the United States. / Naccarelli G.V. [et al.] //Am J Cardiol.- 2009-Vol104- P. 1534–1539.251. Nasr IA. Prevention of atrial fibrillation onset by beta-blockertreatment in heart failure: a meta-analysis. / Nasr IA. [et al.]//Eur Heart J. -2007 – Vol 28(4)- P.457-62.252. Nattel S. Atrial remodeling and atrial fibrillation: mechanisms andimplications./NattelS.[etal.]//CirculationArrhythmiaandElectrophysiology.- 2008-Vol 1(1)-P.
